Bharat Biotech gained an edge in the race among a few entities in the country and several more globally to ready a vaccine for COVID-19 when the Drug Controller General of India (DCGI) cleared its product for human clinical trials.
- The collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) was instrumental in the development of the vaccine. The trials of Covaxin, the vaccine, will begin next month.
- The indigenous, inactivated vaccine has been developed and manufactured in Bharat Biotech’s Bio-Safety Level 3 (BSL-3) High Containment facility located in Hyderbad’s Genome Valley.
- Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future pandemics.